Transformation in Trials
A podcast about the transformations in clinical trial. As life science companies are pressured to deliver novel drugs faster, data, processes, applications, roles and change itself is changing. We speak to people in the industry that experience these transformations up close and make sense of how the pressure can become a catalyst for transformation.
- Update frequency
- every 10 days
- Average duration
- 38 minutes
- Episodes
- 84
- Years Active
- 2022 - 2025
Dr. Daniel Fox: Transforming the balance between sites and sponsors
This week we speak to Dr. Daniel Fox, founder & CEO of Clinical Research Payment Network about how the power dynamic between sponsors and sites is shifting. We speak about the harms of …
Brian D Smith: Transforming the debate on drug pricing vs. innovation
This week we speak to Brian D Smith, professor and author of a brand new book New Drugs, Fair Prices. In the book and on the show Brian suggests that we can have our cake and eat it too…
Graham Dutfield: As drugs become more precise, so needs the patent system
We speak to Graham Dutfield, professor of International Governance and author of That High Design of Purest Gold on the evolution of IP regulation in Pharma and how it could be transfor…
Kristin Carlsson Petri: How pharmacometrics modelling can augment and replace clinical trials
This week we dive into pharmacometrics as a discipline and the potential for replacing and augmenting clinical trials with modelling. We speak to Kristin Carlsson Petri, who is a Direct…
Temitope Keyes: Digitizing clinical trials from paper to decentralized trials
For this episode we explore the evolution of the collaboration and partnership structure between sponsors, CROs and technology vendors in life sciences with Temitope Keyes, Executive Di…
Dr. Elin Haf Davies: Benefits of designing trials for paediatric patients first
We speak to Dr. Elin Haf Davies, CEO and founder of the technology company Apartito. We dive into the topic of designing trials with especially paediatric patients in mind. Elin shares …
Andreas Dam: Transforming how pharma engages with patients and HCPs
Are pharmaceutical companies allowed to engage with patients and HCPs? Judging by how infrequent such interactions are, you might get the sense that it is strictly forbidden. Though suc…
Alexander Gray: Re-defining early-phase development to explore opportunities for assets
The Life Science industry is both known for great leaps of innovation on the product side, and conservatism of process and practice on the other side. In this episode we dive into the a…
Dr. Jack Pearson and Sofie Askervall: Digital contraception and data science-based clinical research
We speak to Dr. Jack Pearson and Sofie Askervall from Natural Cycles about digital contraception and clinical trials based on data science. We explore how an app can become approved by …
Nechama Katan: Psychological safety as a prerequisite for solving wicked problems in life sciences
In this episode Sam and Ivanna dive into the topic of wicked problem solving in life sciences with wicked problem wizard Nechama Katan.
To understand wicked problems we explore complex …
G.T. LaBorde: Arming clinicians with therapeutic options at the point of care
We speak to G.T. LaBorde, the CEO of IllumiCare about clinical trial recruitment at the point of care. Patients want to participate in clinical trials. Health care professionals are wil…
Savva Kerdemelidis and Nicholas Fiorenza: Applying crypto to fund clinical research
We speak to Savva Kerdemelidis and Nicholas Fiorenza, founders of Crowd Funded Cures about alternative financing models for clinical trials and drug development in general.
Grants and e…
Andy Yates: Taking cannabis down from the high to solve unmet medical needs
Sam and Ivanna speak to Andy Yates, the Chief Scientific Officer for Artelo Biosciences about how they are tapping into the potential of the endocannabinoid system to increase treatment…
Jon I. Bergsteinsson on MDR: Separating the data haves from the have-nots
Imagine if all pharmaceutical companies had to re-apply for approval of all existing drugs. Crazy as it seems, this is what is happening in the medical devices space.
Ivanna and Sam spe…
Ivan Jarry: Transplanting the seamlessness of consumer health to clinical trials
We speak to CEO of ObvioHealth, Ivan Jarry, about how clinical trials conducted for consumer products are different from trials in pharma and biotech - and how working with these has en…
Mark Wheeldon: Accelerating reaction time to data trends
Sam and Ivanna speak to Mark Wheeldon, the CEO of Formedix, about that there was once a time where sponsor companies would name their trial variables whatever they wanted, and the regul…
Brian D Smith: Changing your DNA to pursue a novel business model
Could a chimpanzee become a business school professor? He could, if you changed his DNA. In this episode we talk about how to change the DNA of the organization to pursue a new business…
Philip Lyng Madsen: Re-thinking how patients can contribute to research
After a successful career as a strategy consultant, Philip is attracted by the higher purpose of the life sciences space and takes on a quest to find solutions for why clinical trial ti…
Matt Wilson: Transforming how patients benefit from population level research
Matt Wilson guests the show and talks to Sam and Ivanna about how automating consent and recruitment processes can broaden the net in terms of the number of patients involved in clinica…
Ulla Sofie Lønberg and Helle Hartnack on Bias: How behavioral trials can transform access to treatment
“It is always fun to have some data that makes you go Wow! I didn’t know this!”
We speak to Ulla Sofie Lønberg and Helle Hartnack about whether men are risk takers and women reluctant t…